FDG-PET is a good biomarker of both early response and acquired resistance in BRAFV600 mutant melanomas treated with vemurafenib and the MEK inhibitor GDC-0973

FDG-PET is a good biomarker of both early response and acquired resistance in BRAFV600 mutant melanomas treated with vemurafenib and the MEK inhibitor GDC-0973

Bibliographic Details
Main Authors: Baudy, Andreas R, Dogan, Taner, Flores-Mercado, Judith E, Hoeflich, Klaus P, Su, Fei, van Bruggen, Nicholas, Williams, Simon-Peter
Format: Online
Language:English
Published: Springer 2012
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3405466/

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3405466/

Similar Items